Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Post-discharge rivaroxaban does not change VTE risk
Spyropoulos AC et al. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090.
Key clinical point: Rivaroxaban does not significantly reduce the risk of symptomatic VTE when given after discharge.
Major finding: Symptomatic or fatal venous thromboembolism occurred in 0.83% of patients given rivaroxaban, compared with 1.10% of patients given placebo (P = .14).
Study details: The MARINER study was a double-blind, randomized trial involving 12,019 patients. Patients were recently hospitalized for medical illness and had an increased risk of venous thromboembolism.
Disclosures: Funding was provided by Janssen Research and Development. Most of the study authors reported fees or grants from Janssen during the study, and relationships with other companies outside of the submitted work.
Spyropoulos AC et al. N Engl J Med. 2018 Aug 26. doi : 10.1056/NEJMoa1805090.